Alpha Teknova

TKNO

Market cap $257M

Alpha Teknova, Inc. ( TKNO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President, CEO & Director Matthew Lowell - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million

HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, following the close of market.

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Matthew C. Lowell - Chief Financial Officer Stephen Gunstream - President, CEO & Director Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Matthew Moriarty Parisi - KeyBanc Capital Markets Inc., Research Division Matthew Richard Larew - William Blair & Company L.L.C.

Alpha Teknova (TKNO -0.46%), a specialist in custom bioprocess solutions for the life sciences sector, released its results on August 7, 2025. The most important news: Revenue (GAAP) rose by 7%, reaching $10.3 million, and net loss per share (GAAP) narrowed to $0.07, both of which (GAAP) surpassed market expectations.

Second quarter 2025 total revenue was $10.3 million, up 7% from prior year Achieves four consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025.

HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market.

Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Matt Larew - William Blair Chad Wiatrowski - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Teknova First Quarter 2025 Financial Results Conference Call.

First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™  cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million

HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market.